Disease Control With Cabozantinib Plus Atezolizumab in CRPC

(MedPage Today) -- For previously treated patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) continued to show clinically significant activity, according...